Literature DB >> 9439456

Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III).

P S Bachorik1, K L Lovejoy, M D Carroll, C L Johnson.   

Abstract

Serum apolipoproteins (apo) B and AI were measured in a probability sample of the noninstitutionalized US civilian population, ages > or = 4 years, which included non-Hispanic whites, non-Hispanic blacks, and Mexican-Americans. Apo B concentrations were the same in males and females, lower in black males than in other males, low in childhood (approximately 0.80 g/L) and increasing to approximately 1.2 g/L in adults, and higher in younger women on hormones. Apo AI was higher in females than males, higher in blacks than in others, remained constant from childhood to adulthood (approximately 1.35 g/L) in males, but increased with age (approximately 1.30 g/L to approximately 1.55 g/L) in females, and was higher in women taking hormones. These are the first national probability estimates of apo B and apo AI in the US and are referable to the WHO-IFCC First International Reference Materials for apo AI and B.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439456

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  22 in total

1.  Utility of ApoB/ApoA1 ratio for the prediction of cardiovascular risk in children with metabolic syndrome.

Authors:  S Savas Erdeve; E Simsek; Yildiz Dallar; Zeynep Biyikli
Journal:  Indian J Pediatr       Date:  2010-10-06       Impact factor: 1.967

2.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

3.  A young male with familial hypercholesterolemia.

Authors:  Afzalur Rahman; Moeen Uddin Ahmed; A K M Monwarul Islam; Aparajita Karim; Shafiqul A Sarker
Journal:  J Saudi Heart Assoc       Date:  2012-08-04

4.  Black patients present with more severe vascular disease and a greater burden of risk factors than white patients at time of major vascular intervention.

Authors:  Peter A Soden; Sara L Zettervall; Sarah E Deery; Kakra Hughes; Michael C Stoner; Philip P Goodney; Ageliki G Vouyouka; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-09-23       Impact factor: 4.268

5.  Overweight adolescents with type 2 diabetes have significantly higher lipoprotein abnormalities than those with type 1 diabetes.

Authors:  Lynae J Hanks; James Heath Pelham; Shalini Vaid; Krista Casazza; Ambika P Ashraf
Journal:  Diabetes Res Clin Pract       Date:  2016-03-07       Impact factor: 5.602

Review 6.  Treatment of dyslipidemia in children and adolescents.

Authors:  Kathryn Wood Holmes; Peter Oscar Kwiterovich
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

7.  Correlation of metabolic syndrome severity with cardiovascular health markers in adolescents.

Authors:  Arthur M Lee; Matthew J Gurka; Mark D DeBoer
Journal:  Metabolism       Date:  2017-01-13       Impact factor: 8.694

Review 8.  Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Authors:  Allan Sniderman; Patrick Couture; Jacqueline de Graaf
Journal:  Nat Rev Endocrinol       Date:  2010-04-27       Impact factor: 43.330

9.  Metabolic alterations and systemic inflammation in obstructive sleep apnea among nonobese and obese prepubertal children.

Authors:  David Gozal; Oscar Sans Capdevila; Leila Kheirandish-Gozal
Journal:  Am J Respir Crit Care Med       Date:  2008-02-14       Impact factor: 21.405

10.  The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.

Authors:  Sarah Parish; Richard Peto; Alison Palmer; Robert Clarke; Sarah Lewington; Alison Offer; Gary Whitlock; Sarah Clark; Linda Youngman; Peter Sleight; Rory Collins
Journal:  Eur Heart J       Date:  2009-06-11       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.